Roche Signs a License Agreement with Lead Pharma to Develop Oral Therapies for Immune-Mediated Diseases

 Roche Signs a License Agreement with Lead Pharma to Develop Oral Therapies for Immune-Mediated Diseases

Roche Signs a License Agreement with Lead Pharma to Develop Oral Therapies for Immune Mediated Diseases

Shots:

  • Lead Pharma receives ~$11.86M upfront and is eligible to receive funding and ~$307.9 as research, development, regulatory and commercial milestones along with royalties on sales of small molecules
  • The companies will collaborate in research activities up to the selection of a pre-clinical candidate after which Roche will be responsible for the development and global commercialization
  • The R&D collaboration builds on Lead Pharma’s expertise in the discovery, design, and optimization of small-molecule treatments

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post